BioPharmSignal logoBioPharmSignal

Biotech News

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus (ABUS)Arbutus2026-06-25 13:46 ESTClinical readout

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b

Open original release

Related news

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

ABUSArbutus2026-06-25 13:46 EST

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ABUSArbutus2026-06-25 13:46 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-25 13:46 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

View all latest news

Arbutus

Arbutus is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ABUSArbutus2026-06-26 09:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-26 09:30 EST

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

ABUSArbutus2026-06-26 09:30 EST

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

ABUSArbutus2026-06-26 09:30 EST

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-06-26 09:30 EST

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States